Literature DB >> 33390939

Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice.

Ting Bao1,2, Fang He2, Xiaoxia Zhang3, Lili Zhu4, Zhen Wang1, Haixia Lu1, Ting Wang4, Yiwei Li4, Shaoqi Yang2, Hao Wang4.   

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disease worldwide with chronic low-grade inflammation and alteration of gut microbiota. Inulin (INU) has been confirmed to exhibit benefit for metabolic diseases. The aim of this study was to clarify the effects and mechanism of INU on NAFLD inflammation via gut-liver axis.
Methods: C57BL/6 mice were randomly divided into four groups: normal diet group (ND); high-fat diet group (HFD); ND with INU group (ND-INU); HFD with INU group (HFD-INU). After 14 weeks of feeding, mice were sacrificed and associated indications were investigated.
Results: Significant increases of body weight, liver weight, liver biochemical aspartate aminotransferase, alanine aminotransferase, triglyceride, total cholesterol and pro-inflammatory indicators (Lipopolysaccharide, interleukin (IL)-18, IL-1β, TNF-α and IL-6), as well as a reduction of plasma IL-10 were observed in HFD group, while INU treatment restored these abnormal indicators. The ratio of hepatic macrophages (Mψs) and Toll-like receptor 4+ Mψs were both reduced with INU intervention. Nuclear factor-κB, nod-like receptor protein 3, apoptosis-associated speck-like protein and caspase-1 were decreased in HFD-INU group. Additionally, the results of 16S rRNA sequencing and analysis showed that INU administration modulated the composition of gut microbial community in NAFLD mice by up-regulating the abundances of Akkermansia and Bifidobacterium as well as down-regulating the abundances of Blautia and the ratio of Firmicutes/Bacteroidetes. Short-chain fatty acids including acetic acid, propionic acid and butyric acid, were increased with INU treatment. Correlation analysis revealed close relationships among inflammatory indicators, metabolic indicators as well as gut microbiota/its metabolite short-chain fatty acids.
Conclusion: INU prevents NAFLD via modulating gut microbiota and suppressing Lipopolysaccharide-Toll-like receptor 4-Mψ-Nuclear factor-κB-nod-like receptor protein 3 inflammatory pathway via the gut-liver axis.
Copyright © 2020 Bao, He, Zhang, Zhu, Wang, Lu, Wang, Li, Yang and Wang.

Entities:  

Keywords:  gut microbiota; inulin; macrophage; nod-like receptor protein 3 inflammasome; non-alcoholic fatty liver disease

Year:  2020        PMID: 33390939      PMCID: PMC7774311          DOI: 10.3389/fphar.2020.558525

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  10 in total

1.  The effect of inulin-type fructans on the intestinal immune function of antibiotic-treated mice.

Authors:  Wenjing Zeng; Qin Zhang; Gang Feng; Gongliang Liu; Fenglin Wu; Han Shen; Hongwei Shao; Changli Tao
Journal:  Appl Microbiol Biotechnol       Date:  2022-04-04       Impact factor: 4.813

Review 2.  The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Rosa Martín-Mateos; Agustín Albillos
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

Review 3.  Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.

Authors:  Ji-Won Park; Sung-Eun Kim; Na Young Lee; Jung-Hee Kim; Jang-Han Jung; Myoung-Kuk Jang; Sang-Hoon Park; Myung-Seok Lee; Dong-Joon Kim; Hyoung-Su Kim; Ki Tae Suk
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 4.  The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.

Authors:  Kevin De Muynck; Bart Vanderborght; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

Review 5.  The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.

Authors:  Lingxuan An; Ulrich Wirth; Dominik Koch; Malte Schirren; Moritz Drefs; Dionysios Koliogiannis; Hanno Nieß; Joachim Andrassy; Markus Guba; Alexandr V Bazhin; Jens Werner; Florian Kühn
Journal:  J Gastrointest Surg       Date:  2021-11-03       Impact factor: 3.267

6.  Dietary α-Linolenic Acid-Rich Flaxseed Oil Ameliorates High-Fat Diet-Induced Atherosclerosis via Gut Microbiota-Inflammation-Artery Axis in ApoE -/- Mice.

Authors:  Yiwei Li; Zhi Yu; Yuanyuan Liu; Ting Wang; Yajuan Liu; Zhixia Bai; Yi Ren; Huiyan Ma; Ting Bao; Haixia Lu; Rui Wang; Libo Yang; Ning Yan; Ru Yan; Shaobin Jia; Xiaoxia Zhang; Hao Wang
Journal:  Front Cardiovasc Med       Date:  2022-02-28

7.  Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.

Authors:  Yingying Liu; Yingying Tan; Jiaqi Huang; Chao Wu; Xiaotian Fan; Antony Stalin; Shan Lu; Haojia Wang; Jingyuan Zhang; Fanqin Zhang; Zhishan Wu; Bing Li; Zhihong Huang; Meilin Chen; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 8.  Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.

Authors:  Xiang Chen; Menghan Liu; Jun Tang; Ning Wang; Yibin Feng; Haotian Ma
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

9.  Soluble Fiber Inulin Consumption Limits Alterations of the Gut Microbiota and Hepatic Fatty Acid Metabolism Caused by High-Fat Diet.

Authors:  Mayssa Albouery; Alexis Bretin; Bénédicte Buteau; Stéphane Grégoire; Lucy Martine; Ségolène Gambert; Alain M Bron; Niyazi Acar; Benoit Chassaing; Marie-Agnès Bringer
Journal:  Nutrients       Date:  2021-03-23       Impact factor: 5.717

10.  Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level.

Authors:  Carlos Pérez-Monter; Alejandro Álvarez-Arce; Natalia Nuño-Lambarri; Ivonne Escalona-Nández; Eva Juárez-Hernández; Norberto C Chávez-Tapia; Misael Uribe; Varenka J Barbero-Becerra
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.